Rua Bioscience (NZX: RUA), the Tairāwhiti-based medicinal cannabis company, has received verification that its first medicinal cannabis product meets the NZ Medicinal Cannabis Agency’s (Medsafe’s) quality standards, enabling the company to distribute its first medicine in New Zealand.
The approval of the product means that New Zealand patients and prescribers can include the Rua product in their treatment plan. Rua intends to distribute product by the end of Q1, early Q2 2022. It will be made available as a prescription-only medicine through GPs and specialists. Rua be will manufacturing the medicine in its purpose-built facility in Gisborne, having gained Good Manufacturing Practice (GMP) certification for the product earlier this year.